March 2026 FDA accelerated approval of AVLAYAH gave Denali its first human validation that an intravenously delivered biologic can cross the blood-brain barrier and produce measurable brain effects.
At AAIC 2026 in London, Denali argued the approval confirms its transferrin-receptor TransportVehicle platform can ferry enzymes, antibodies and oligonucleotides into the brain at therapeutic levels.
Preclinical data showed 10- to 30-fold higher brain exposure for antibodies and enzymes, and more than 1,000-fold for oligonucleotides, compared with unmodified systemic drugs.
The approval still rests on surrogate evidence of brain enzyme delivery and substrate clearance in pediatric Hunter syndrome patients, with confirmatory trials on long-term neurological benefit still pending.
Denali said the platform could reshape treatment beyond Alzheimer's, including tau, ALS, FTD and other CNS diseases now reliant on intrathecal injection or surgery.
Denali’s key unlocks the brain, but can its Alzheimer's drug succeed where its Parkinson’s therapy failed?
By hijacking the brain's iron pathway for drug delivery, are we risking unforeseen long-term side effects?
Breaking the Blood-Brain Barrier: FDA Approves AVLAYAH™ for Hunter Syndrome, Ushering in a New Era for Neurological Drug Development
Overview
On March 25, 2026, the FDA approved Denali Therapeutics’ AVLAYAH™, the first brain-penetrant biologic designed to treat the neurological symptoms of Hunter syndrome. This approval marks a major breakthrough, as Denali successfully developed a therapy that can cross the blood-brain barrier—a challenge that has limited treatments for many brain diseases. The success of AVLAYAH™ not only brings hope to patients with Hunter syndrome but also opens new possibilities for treating other central nervous system disorders. The FDA’s decision highlights a commitment to regulatory flexibility, encouraging further innovation in CNS therapeutics.